secwatch.observer — SEC 8-K summary
======================================

Issuer:     LEXICON PHARMACEUTICALS, INC. (LXRX)
CIK:        0001062822
Form:       8-K
Filed at:   2025-03-06T23:59:59+00:00
Accession:  0001062822-25-000008
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lexicon reports Q4 net loss $33.8M; pilavapadin 10mg advances to Phase 3
------------------------------------------------------------------------

- Q4 net loss $33.8M ($0.09/shr) vs $49.8M loss in Q4 2023; revenue $26.6M including $25M Viatris upfront.
- Phase 2b PROGRESS study of pilavapadin met objectives; 10mg dose showed meaningful pain reduction vs placebo; Phase 3 targeting 2025.
- Cash and investments $238.0M at Dec 31, 2024, up from $170.0M year-end 2023; full-year net loss $200.4M.
- Company ceased active INPEFA promotion and discontinued Zynquista launch prep after FDA CRL; leaner R&D-focused organization.
- LX9851 IND on track for 2025; sotagliflozin Phase 3 SONATA HCM trial enrolling with 500-patient target.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1062822/000106282225000008/0001062822-25-000008-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1062822/000106282225000008/lxrx-20250306.htm
  HTML page:      https://secwatch.observer/filing/0001062822-25-000008

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer